American University in Cairo

AUC Knowledge Fountain
Theses and Dissertations

Student Research

6-1-2018

HeLa cell line, a model to study the role of cofactor of BRCA1 in
cervical cancer
Noha Saad Abd Elhamied

Follow this and additional works at: https://fount.aucegypt.edu/etds

Recommended Citation

APA Citation
Abd Elhamied, N. (2018).HeLa cell line, a model to study the role of cofactor of BRCA1 in cervical cancer
[Master's Thesis, the American University in Cairo]. AUC Knowledge Fountain.
https://fount.aucegypt.edu/etds/1344

MLA Citation
Abd Elhamied, Noha Saad. HeLa cell line, a model to study the role of cofactor of BRCA1 in cervical
cancer. 2018. American University in Cairo, Master's Thesis. AUC Knowledge Fountain.
https://fount.aucegypt.edu/etds/1344

This Master's Thesis is brought to you for free and open access by the Student Research at AUC Knowledge
Fountain. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of AUC
Knowledge Fountain. For more information, please contact thesisadmin@aucegypt.edu.

School of Sciences and Engineering

HELA CELL LINE, A MODEL TO STUDY THE ROLE
OF COFACTOR OF BRCA1 IN CERVICAL CANCER

A Thesis Submitted to the
Biotechnology Master’s Program
In partial fulfilment of the requirements for the
Degree of Master of Science

By

Noha Saad Abd Elhamied
Bachelor of Pharmaceutical Sciences

Under the supervision of

Dr. Asma Amleh
Associate Professor, Department of Biology
The American University in Cairo
May 2018

The American University in Cairo
School of Sciences and Engineering (SSE)

HELA CELL LINE, A MODEL TO STUDY THE ROLE OF
COFACTOR OF BRCA1 IN CERVICAL CANCER

A Thesis Submitted by
Noha Saad Abd Elhamied
To the Biotechnology Master’s Program
May 2018

In partial fulfilment of the requirements for
The degree of Master of Science in Biotechnology

Has been approved by

Thesis Committee Supervisor/Chair
_______________________________________________
Affiliation ______________________________________
Thesis Committee Reader/Examiner
______________________________________________
Affiliation _____________________________________
Thesis Committee Reader/Examiner
______________________________________________
Affiliation ______________________________________
Thesis Committee Reader/External Examiner
______________________________________________
Affiliation _____________________________________
________________

_____________

Dept. Chair/Director

Date

Dean

______________
Date

ii

_______________

DEDICATION

To my parents, Saad Abd Elhamied Mohamed and Faten Ahmed Mosleh; this is
because of you.
Thank you for never letting me give up

iii

ACKNOWLDEGMENTS
All praise be to Allah

I would like to express my deepest gratitude to my supervisor Dr. Asma Amleh for her
continuous guidance and support during my thesis work. I will always be grateful for the time
and effort she spent on putting me on the right path of scientific research. Her valuable
discussions and suggestions were essential for the progress of the project. I will always be
motivated by her dedication to her work and to science.
I sincerely thank Dr. Amleh’s research team members; past and present, who have been a great
support throughout this journey. I am deeply grateful to Menna Elfar, Menna Ghouraba, Myret
Ghabriel, Nancy Ahmed and Sheri Saleeb for their brain storming, help in the laboratory work,
valuable comments and for readiness to share their scientific knowledge whenever needed. I
would like to acknowledge Eman Elzenini for her precise documentation and valuable notes
that helped me a lot. I would like also to thank Razan Masad for her support and for her
guidance during my first experiments. It was such a blessing to work with this amazing team.
I would like to acknowledge Dr. Ahmed Moustafa for his continuous support to the
Biotechnology program students. I would also like to extend my sincere appreciation to all my
professors at the AUC, especially Dr. Hamza El Dorry who has taught me a lot during my first
year in the program. I deeply recognize Amged Ouf for all his efforts and time spent on
ensuring that our research work continues smoothly.
I am sincerely thankful to Mr. Moataz Al-Alfi for partially funding my studies at the AUC.
Also, I would to express much gratitude to the AUC for the research grant that supported this
work.
Last but not least, my deepest appreciation goes to my beloved family for their support; my
husband Ashraf Aboelfadl and my amazing sons Mohamed, Ali and Hamza for their caring,
patience and for all the time that I have been taking from us as a family to put into my studies
and research work. I am truly thankful to my precious brothers, Tamer and Ahmed, and my
sister in law Jailan Rashed for the positive energy and the unlimited emotional support they
have been giving me throughout this learning journey.

iv

HELA CELL LINE, A MODEL TO STUDY THE ROLE OF
COFACTOR OF BRCA1 IN CERVICAL CANCER
ABSTRACT

Being one of the four subunits that makes up the Negative Elongation Factor Complex (NELF),
Cofactor of BRCA1 (COBRA1); also known as NELF-B, is able to regulate a number of genes
involved in cellular proliferation, metabolism, cell cycle progression and DNA repair. In
addition, COBRA1 was shown to interact with other transcription factors such as BRCA1, AP1 complex and several nuclear receptors. Despite the evidences that suggest COBRA1 as a
potential player involved in the progression of a number of cancers, its role in cervical cancer
has not been previously investigated. To date, it has been studied in breast, upper
gastrointestinal and liver cancers. The main objective of our study was to investigate the
potential involvement of COBRA1 in cervical cancer progression. We first did in-silico
analysis of the expression patterns of COBRA1 in cervical cancer tissues relative to normal
cervical tissues using the publicly available Oncomine Cancer Microarray Database. Search
results revealed a significant upregulation of COBRA1 in two mRNA microarray datasets.
RNA interference technique was then used to knockdown COBRA1 expression in cervical
cancer cell line, HeLa. Once a successful siRNA mediated silencing at the RNA and protein
levels of COBRA1 was established and confirmed through semi-quantitative Reverse
Transcription Polymerase Chain Reaction (RT-PCR) and Western Blot, we investigated its
consequences on proliferation, migration and survival of HeLa cells. Interestingly, COBRA1
depletion resulted in a significant increase in the mRNA expression of Trefoil Factor 1 (TFF1)
accompanied by a subsequent decrease in the β-catenin mRNA levels. These findings suggests
an effect for COBRA1 on the Wnt/β-catenin signalling pathway, which could be mediated
through TFF1. In addition, COBRA1 silencing resulted in significant decrease in the
expression of survivin 2B and survivin DeltaEX3 isoforms while the observed decrease in
survivin wild type form was found to be statistically insignificant. Survivin is known to play a
major role in cancer cells proliferation and survival. Yet, the finding that the noted decrease in
β-catenin and survivin expression was not reflected on the proliferation and migration abilities
of HeLa is not conclusive and requires further investigations. Taken together, these findings
could help as an initial step in identifying the role of COBRA1 in cervical cancer tumorigenesis.
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1. LITERATURE REVIEW

1.1 Cervical Cancer
1.1.1 Incidence and Epidemiology
Cervical cancer is the fourth most frequent cancer among women worldwide with 527,600
new cases being diagnosed annually. It is the fourth cause of cancer related deaths and
responsible for around 265,700 deaths globally per year. Cervical cancer primarily affects
developing countries, being the second most commonly diagnosed type of cancer and third
leading cause of cancer death among females in those countries (Arbyn et al., 2011; Torre
et al., 2015). Over 85 % of all cervical cancer cases and related death occurs in developing
countries. The incidence rates are lowest in Australia/New Zealand, Northern America and
Western Europe while the highest rates are in Eastern, Western and Southern Africa, South
America, South Central Asia together with Melanesia. Notably, the most affected are socioeconomically active young women who are in the prime of their lives (Arbyn et al., 2011).
This variation is mainly attributed to differences in the availability of efficient screening
tools allowing for the early detection and removal of precancerous lesions. (Arbyn et al.,
2011; Torre et al., 2015).
Based on the information available from ICO/IARC Information Centre on HPV and
Cancer, cervical cancer is the 13th most frequent cancer among women in Egypt and ranks
as the 10th most frequent cancer among women between the ages of 15 and 44 years. It
accounts for a total number of 866 cancer new cases and 373 cancer related death annually
(http://www.hpvcentre.net, last accesses April 2018) (Bruni et al.,2017).

1.1.2 Aetiology
Almost all cervical tumours (99%) develop as a result of persistent human papilloma virus
(HPV) infection (Colombo et al., 2012). Human papillomaviruses are DNA viruses that
infect and replicate in cutaneous and mucosal epithelia. Oncogenic subtypes such as HPV
16 and 18 account for 70% of all cervical malignancies. Other oncogenic subtypes include
1

HPV 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82. Studies suggest that genetic
sequences variations among different HPV subtypes could produce differences in their
oncogenic potentials and hence different clinical outcomes among CC patients. (Dasari,
Wudayagiri, & Valluru, 2015).
When HPV infection occurs, it is usually eliminated by the immune system. If viral
elimination does not happen, prolonged presence of the oncogenic HPV subtype and
increased viral load occur leading to higher chances of developing a precancerous cervical
intraepithelial neoplastic (CIN) lesion, which can progress to invasive cervical tumors. Risk
cofactors that can halt the process of HPV elimination include the presence of defective
immune response as with human immunodeficiency virus (HIV) infection and the use of
organ transplant rejection drugs. Smoking can also be a cofactor for the development of
chronic HPV infection (Newton & Mould, 2017; Uyar & Rader, 2014). It is worth
mentioning that also estrogen contributes to HPV infection persistence and the resulting
neoplastic progression via

increasing viral oncogenes expression (S. H. Chung,

Franceschi, & Lambert, 2010; Nair et al., 2005).
Cervical cancer is more common than other HPV derived cancers (vagina, vulva, penile,
anal and oropharynx) due to the presence of a transformation zone on the cervix. This is
mainly an area of exposed columnar tissue on the cervix known as the ectropion which
undergoes squamous metaplasia and transforms into squamous tissue, hence the label
transformation zone. This area is highly susceptible to the effects of oncogenic HPV
(Newton & Mould, 2017).

1.1.3 Surveillance and Diagnosis
Cervical epithelial tumors are classified by WHO into three main categories; squamous (7080%), adenocarcinoma (10-15%) and other epithelial tumors (including neuroendocrine
tumors and undifferentiated carcinoma) (Colombo et al., 2012). Despite the decline in the
incidence of CC in developed countries, several reports during the past 40 years have
documented an increase in relative distribution of the adenocarcinoma subtype compared to
squamous cell carcinoma in these countries (Gien, Beauchemin, & Thomas, 2010;
Hildesheim & Berrington de González, 2006) .
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Symptoms associated with early stages of CC are usually non-specific and are common with
other clinical conditions. The most common sign suggesting the presence of cervical cancer
is bleeding; which could be postcoital, intermenstrual or postmenopausal bleeding. Other
symptoms include blood stained vaginal discharges, pelvic pain and suspicious cervix on
examination. The lateral spread of the tumor which is present in advanced stages of CC can
result in the occurrence of loin pain caused by hydro-nephrosis, sciatica with tumor
compressing nerve roots and deep vein thrombosis causing swollen legs (Newton & Mould,
2017).
Screening techniques for CC mainly include cell cytology and HPV-DNA testing. The basic
widely used cytology screening test for CC is the Papanicolaou (Pap) smear. It involves
sampling the epithelial cells from the surface of cervix and assessing their morphology.
Implementing this screening method in some parts of the world has resulted in a significant
decrease in the incidence of CC. Still, the Pap smear test suffers from lack of sensitivity,
being of subjective nature and it might not be as efficient for the detection of
adenocarcinoma subtype. In 2008, molecular HPV-DNA testing has been employed as a
new screening approach with greater diagnostic sensitivity and reproducibility especially
when detecting precancerous stages (Colombo et al., 2012).
Although cervical cancer can be detected in its early stages by the above mentioned
techniques, hence can be successfully eradicated through surgery, curative treatments do not
yet exist for advanced, recurrent or metastatic stages of the disease (Cao, Liu, Yang, Chen,
& Zheng, 2017).

1.1.4 Vaccination
The notion that HPV infection is a main contributor in the development of CC has facilitated
the measures taken for CC prevention through the development of HPV vaccines. HPV
vaccination has been the primary prophylactic strategy for CC with a number of vaccines
being developed and are of wide use in some countries across the world. In 2006, FDA
approved Gardasil [Merck and Company, Whitehouse Station, NJ], a quadrivalent vaccine
developed for the prevention of diseases associated with infection with diﬀerent HPV types
(6, 11, 16 and 18). Two additional vaccines were approved for use in 2009 and 2014:
Ceravix [GlaxoSmithKline, Brentford, UK], a bivalent vaccine against HPV types 16 and
3

18, and Gardasil 9 [Merck], the most advanced prophylactic vaccine to date, which protects
against nine HPV types: 6, 11, 16, 18, 31,33, 45, 52 and 58 (Newton & Mould, 2017). Some
concerns have been raised regarding the use of vaccines which are mainly that they were
tailored towards the population within the developed countries with decreased potency in
developing countries; where they are needed most. In addition, the high cost stands against
the wide scale use of the vaccines in the developing parts of the world.
It is highly recommended that all women; including those previously vaccinated, continue
to be screened. This is mainly because HPV vaccines do not have any therapeutic effects so
they cannot protect against already established infections, together with the fact that they do
not protect against all of the other types of high risk HPVs that can cause cervical cancer.
Unfortunately, many low-resource countries do not have the technical and public health
infrastructure needed to support Pap smear testing; the most common screening tool for
cervical cancer in more developed countries (Pyeon et al., 2007; Torre et al., 2015).

1.1.5 Prognosis and Available Treatments
Prognostic factors for survival rate in CC patients include the clinical stage, lymph node
state, size of the tumor and grade (Gien et al., 2010). The cancer stage and tumour size are
currently the basis for choosing suitable treatment. Surgical options for patients with early
stage disease (FIGO stage IA- IB1, in which the lesion is confined to the cervix) include
cervical conisation, hysterectomy and pelvic trachelectomy, with 5 years survival rates that
exceeds 90%. In stages ⅡB2- ⅢB, it becomes more challenging to obtain negative surgical
margins; in these instances surgery, chemotherapy and/or radiation is given in combination
aiming to improve treatment results (Colombo et al., 2012; Newton & Mould, 2017).
For women with cancers that have spread within the region, the 5-years survival rates falls
to 57% and for cancers which have metastasised to distant organs survival is estimated at
only 17%. For the more advanced stages of the disease (stage Ⅳ), surgery could not remain
an available option and the treatment is usually palliative with the objective of controlling
symptoms and improving quality of life (Colombo et al., 2012; Newton & Mould, 2017).
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1.1.6 Molecular Biology of CC Progression
Identifying the molecular mechanisms involved in cervical carcinogenesis is essential for
developing therapeutic targets and biomarkers that would allow for better management of
the disease. The fact that not all women infected with HPV will develop CC has shed the
light that other factors in addition to HPV infection are involved. HPV DNA integration
into the host chromosomal genome is a crucial step in cervical cancer progression and is
almost present in all invasive CC. This integration usually occurs at common fragile sites in
the human genome. During this process, cleavage occurs at the E1/E2 genes cleavage site
leading to deletion of E2 gene, thus leading to overexpression of E6 and E7 viral
oncoproteins whose expression is repressed by E2. This in turn promotes genomic
instability, accumulation of secondary mutations, and malignant transformation of the host
cells. In addition, the virus integrates into host genes and regulatory elements with the
possibility of inducing structural alteration of the host genome and transcriptional
deregulation of normal genetic expression (Pérez-Plasencia, Dueñas-Gonzalez, & BustosMartínez, 2008; Uyar & Rader, 2014).
The expression of certain proteins of the host cells such as those involved in cell division
and apoptosis are altered by the viral oncoproteins. The E7 protein can bind to tumorsuppressor proteins of the retinoblastoma (pRB) family, and degrades them leading to
uncontrolled activation of E2F transcription factors which in turn stimulate expression of
genes involved in S phase of the cell cycle. In addition, E7 interacts with the cyclindependent kinases (CDK) inhibitors, p21 and p27, promoting the transition from G1 to S
phase. The E6 protein in turn halts the pro-apoptotic effect of p53, BCL2 Associated X
protein (BAX), BCL2 Antagonist /Killer (BAK) and c-Myc. The E5 viral protein is mainly
active during early stages of the disease before viral DNA integration occurs. One of its
main activities is the interaction with epidermal growth factor receptor (EGFR) leading to
increased cellular proliferation rate (De Freitas, Coimbra, & Leitão, 2014).
Improved understanding and increased knowledge of the molecular biology events
associated with CC progression will help develop novel treatment strategies. The main
interest of this study is COBRA1 gene, which have been recently identified for having a
potential role in the progression of several cancers.
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1.2 Cofactor of BRCA1
1.2.1 Identification
Cofactor of BRCA1; also known as NELF-B, was first isolated from a human ovary cDNA
library. It is located on chromosome 9 and encodes a 580 amino acid protein with 3 repeats
of the LXXLL motif, where L-leucine and X-any amino acid. It has been first identified as
a BRCA1 interacting protein via a yeast two-hybrid assay. Results suggested that BRCA1dependent unfolding of higher levels of chromatin structure is likely to be partially mediated
through recruitment of COBRA1to the BRCT1 domain of BRCA1 (Ye et al., 2001). Later
in 2003, COBRA1 was found to be the same as NELF-B, which is one of the four subunits
that constitute the negative elongation factor (NELF) complex (Narita et al., 2003). It has
been proved that COBRA1 is involved in the transcriptional regulatory machinery of the
cells and is involved in the regulation of multiple considerably important genes (Aiyar et
al., 2004; Aiyar, Blair, Hopkinson, Bekiranov, & Li, 2007; Aiyar, Cho, Lee, & Li, 2007).
In addition, in-vivo studies by Amleh et al., (2009) shed the light on an important role for
COBRA1 in early embryogenesis where the general knockout of COBRA1 in murine
embryos was found to be lethal. COBRA1 was also found to be involved in maintaining the
undifferentiated state of mouse ESCs (Amleh et al., 2009).

1.2.2 COBRA1 and Transcription factors
With no DNA binding domain of its own, COBRA1 was found to regulate the transcription
of its downstream target genes via interacting with other transcription factors including
BRCA1, nuclear receptors and AP-1 complex (Aiyar et al., 2004; Sun, Blair, Aiyar, & Li,
2007; Ye et al., 2001; Zhong et al., 2004). This network of interactions suggests COBRA1
being involved in the regulation of multiple cellular processes as proliferation, cell survival
and tumorigenesis. An overview of the available knowledge on COBRA1 interactions with
various transcription factors will be discussed next.

6

1.2.2.1 BRCA1
The Breast Cancer Type 1 susceptibility protein (BRCA1) gene; encoding a 1,863 amino
acid protein, was identified and cloned in 1994 (Rosen, Fan, Pestell, & Goldberg, 2003).
It has been linked to breast and ovarian cancers, with mutations in BRCA1 accounting for
only 2-3% of all breast cancers; yet its expression is frequently reduced or absent in sporadic
cancers. The tumor suppressor activity of BRCA1 has been extensively investigated and
have been attributed to its involvement in several molecular functions including DNA repair,
DNA damage response, cell cycle check points, regulation of certain transcriptional
pathways and apoptosis (Rosen et al., 2003).
In accordance with BRCA1’s reported role as tumor suppressor in breast cancer, several
studies had shed the light on the role of COBRA1 as being a breast cancer tumor suppressor
as well. Aiyar et al., 2007 used gene expression profiling in T47D breast cancer cell line to
uncover a significant overlap of the genes that are regulated by COBRA1 and BRCA1, of
which multiple genes are known to be involved in breast cancer progression (Aiyar, Cho,
et al., 2007).

1.2.2.2 NELF Complex
COBRA1 was identified as being the same as NELF-B, one of the four subunits that makes
up the negative elongation factor (NELF) complex (Narita et al., 2003). This complex is
made up of NELF-A (66 kDa), NELF-B (62 kDa), NELF-C (60 kDa) or NELF- D (59 kDa)
and NELF-E (46 kDa). Being translational variants of a common mRNA, either NELF-C or
NELF-D will be present at a certain point within the NELF complex. The core of the
complex consists of NELF-C/D together with NELF-B bridging NELF-A; having the
RNAPⅡ binding domain and NELF-E; having the RNA binding domain (Narita et al.,
2003; Sims, Belotserkovskaya, & Reinberg, 2004).
NELF complex together with DRB- sensitivity inducing factor (DSIF) have been associated
with a process known as promoter proximal pausing, in which the RNA polymerase Ⅱ
(RNAPⅡ) is stalled 30-50 bps downstream of the transcription initiation site (Yamaguchi
et al., 1999). The kinase activity of the positive transcription elongation factor b (P-TEFb)
causes the release of paused polymerase into productive elongation phase again by
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phosphorylating the serine 2 position of the C-terminal domain in the largest subunit of
RNAPII (Sun & Li, 2010).
It is worth mentioning that all the four subunits; NELF-A, NELF-B, NELF-C/D and NELFE, are required for the assembly of a functional NELF complex (Narita et al., 2003). This
was found consistent in several studies, where the knockdown of any of the four subunits
resulted in co-depletion of the other ones at the protein level but not at the mRNA level
(Narita et al., 2003; Sun et al., 2008; Sun & Li, 2010).
The NELF complex mediated stalling of RNAPⅡ has been recently found to have functional
consequences other than transcription inhibition. Studies done in Drosophila revealed that
stalled RNAPⅡ was associated with the promoters of around 50% of most of its highly
expressed genes indicating a role in fine tuning of gene expression rather than inhibiting it,
thus potentiating genes for future activation (Gilchrist et al., 2008, 2010). In addition, recent
studies in human cells have been proposing a positive role for NELF Complex in the
transcription activation of a large number of genes particularly those involved in cell cycle
regulation (Sun & Li, 2010). Based on results obtained from gene expression profiling
analysis following depletion of NELF subunits in T47D breast cancer cell line, it was
suggested that NELF complex mainly functions in sustaining active expression of target
genes rather than inhibiting it through promoting association of RNAPⅡ with the actively
transcribing genes rather than preventing the active transcription elongation. This was
thought to be mediated through maintaining a permissive chromatin structure and preventing
nucleosomal encroachment at promoters of target genes (Sun et al., 2011; Sun & Li, 2010).

1.2.2.3 AP-1 Complex
COBRA1 has no DNA binding domains, hence its ability to regulate genetic expression is
mainly through interaction with other transcription factors. In addition to its roles with
BRCA1 and as a functional component of NELF complex, it was shown to act as a
regulatory transcription cofactor for Activator Protein-1 complex (AP-1), whose signalling
pathways plays a major role in determining the cellular fate (Zhong et al., 2004).
The activating protein1 (AP-1) is a transcription factor which regulates basal and inducible
transcription of multiple genes having the consensus AP-1 sites. Within the complex cellular
context, AP-1 activity is regulated in response to several stimuli including cytokines, stress
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signals, growth factors, and infections in addition to oncoproteins (Hess, Angel, &
Schorpp-Kistner, 2004)
AP-1 have been found to be implicated in the control of both cell survival and apoptotic
pathways (Shaulian & Karin, 2001). The modulation of this decision was found to be
dependent on cell lineage, abundance of different AP-1 complex members,
microenvironment, type of stimulus and the presence of regulatory transcription cofactors
(Hess et al., 2004; Shaulian & Karin, 2001).
COBRA1 has been proposed as one of the cofactors affecting AP-1 activity. In 2004, a study
by Zhong et al. revealed that the overexpression of COBRA1 inhibited AP-1 mediated
transcriptional activation in transfected cells with the opposite effect observed when
silencing of COBRA1 with small interfering RNA was applied. This effect was attributed to
a physical interaction between COBRA1 and AP-1 family members’ c-Jun and c-Fos
causing an inhibition of the AP-1 transactivation of target genes. Given that the activity of
AP-1 is effective on the cellular proliferation, differentiation, survival, apoptosis and
malignant transformation, it was proposed that COBRA1; by acting as a cofactor in AP-1
transactivation, is involved in the regulation of these cellular processes as well (Zhong et
al., 2004).
1.2.2.4 Nuclear receptors
The ligand binding activation of ER induces conformational changes and activation of the
receptor and its subsequent binding to the estrogen responsive elements in promoters of
target genes (Aiyar et al., 2004; S. Chung, Franceschi, & Lambert, 2010).
A novel role for COBRA1 in the regulation of hormone-responsive transcription was
identified by Aiyar et al., (2004). It was found that COBRA1 can bind directly to the
activated ER-α and repress genetic transcription mediated through ER-α. These findings
supported a role for COBRA1 in suppressing estrogen-dependent growth of breast cancer
cells (Aiyar et al., 2004). This was attributed to the previously identified 3 repeats of the
LXXLL motif present in COBRA1 protein needed for NR-binding (Ye et al., 2001).
COBRA1 was found to interact with variable affinities to other nuclear receptors as the
progesterone receptor B (PRB), androgen receptor (AR) and glucocorticoid receptor (GR).
The strongest binding affinity was found to be related to the AR resulting in the subsequent
regulation of the AR-dependant transcription (Sun et al., 2007).
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1.3 Role of COBRA1 in Cancer
The biological role of COBRA1 in cancer pathogenesis is not fully understood but there is
a growing body of evidences which suggests that COBRA1 plays a role in the malignant
transformation, proliferation and invasion of cancer cells. Previous findings are suggesting
a cancer-type dependent role for COBRA1, with different expression patterns in different
cancers. To date it has been studied in breast, UGCs and liver cancers.
1.3.1 Breast Cancer
The identification of COBRA1 as a BRCA1 interacting protein has highlighted the
possibility of COBRA1 having a role in breast cancer. Several studies have previously
identified COBRA1 to act as a tumor suppressor in breast cancer. In a study by Zhu et al.
(2004), COBRA1 mRNA and protein levels were found to be differentially expressed in
different breast cancer cell lines. Its role in the regulation of breast cancer growth was
proposed based on the identified physical interaction between endogenous COBRA1 and
BRCA1 within the examined cells. In addition, both ER- positive and ER-negative cell lines
were found to express COBRA1 suggesting absence of correlation between ER and
COBRA1 expression (J. Zhu et al., 2004). Another study in 2004 done by Aiyar et al. on
breast cancer cells showed that COBRA1; as being the NELF-B subunit of NELF complex,
binds to the activated ER-α causing the RNA polymerase II to pause at the promoter
proximal region and thus attenuate the ERα mediated transcription activation. The use of
siRNAs targeting COBRA1 in T47D breast cancer cells resulted in increased cellular
proliferation. However this increase was observed only when exogenous estrogen was added
to culture, indicating a possible role for COBRA1 in suppressing the estrogen-mediated
growth of breast cancer and expression of genes such as the Trefoil Factor 1(TFF1) known
to be associated with breast cancer progression and metastasis (Aiyar et al., 2004). This was
confirmed in another study where COBRA1 knockdown did not affect the cellular
proliferation of T47D cells in the absence of estrogen (Sun & Li, 2010). In accordance,
COBRA1 expression was found to be reduced in patients with metastatic breast cancer and
local recurrence (Sun et al., 2008).
1.3.2 Upper Gastrointestinal Cancers
COBRA1 has been identified as a novel oncogene in UGCs with high expression levels of
COBRA1 mRNA and protein observed in tumor samples compared to normal (McChesney
et al., 2006). The overexpression of COBRA1 was found to be accompanied by
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downregulation of TFF1 expression, which has several protective and healing roles in upper
gastrointestinal tract and has been reported to be a tumor suppressor in UGCs (Tanaka et
al., 2013). This was found contradictory to its previously reported role as tumor suppresser
in breast cancer (Aiyar et al., 2004). In addition, examining the regulatory effects of
COBRA1 on TFF1 gene expression in gastric adenocarcinoma cell lines revealed its role as
inhibitor of TFF1 expression was estrogen independent and NELF-E independent. It was
found to occur by COBRA1 inhibiting the AP-1 complex activation of the TFF1 gene in
UGC, while in breast cancer, COBRA1 inhibits hormone-dependent activation of TFF1
through recruitment to the activated ER-α. The results highlighted the ability of COBRA1
to regulate definite transcription processes in different cells and tissue types via interaction
with different transcription factors (McChesney et al., 2006).
1.3.3 Liver Cancer
Studies done in Dr. Amleh’s lab have revealed a potential involvement of COBRA1 in HCC
pathogenesis. Initially, Kamel (2012) has observed frequent overexpression of COBRA1 in
HCC tumor tissues relative to their corresponding non-tumor specimens. Yet this study was
limited with the small sample number which made it difficult to statistically correlate
COBRA1 expression to clinicopathological parameters (Kamel, 2012). To further explore
the role of COBRA1 as a potential prognostic marker for HCC, Youssef et al. (2016)
investigated the protein and mRNA expression of COBRA1 across four different cell lines
representing different grades of HCC. Results revealed a gradual decrease in expression of
COBRA1 with increased HCC aggressiveness. The highest expression was observed in the
low grade HepG2 cell line and the lowest expression in the high grade SNU-387 (Youssef,
Shawer, Afify, & Amleh, 2016). In 2017, Silencing of COBRA1 expression in HepG2 cell
line using RNA interference resulted in a significant decrease in the cellular proliferation
and migration rates of HepG2. This was associated with a significant decrease in the mRNA
expression levels of the proliferation marker Ki-67 and the proto-oncogene survivin (El
Zeneini, Kamel, El-Meteini, & Amleh, 2017).
1.3.4 Other Cancers
In a study done on ovarian cancer, COBRA1 was found to be a downstream target of the
RAS/MAPK signaling pathway. The inactivation of this signaling pathway in ovarian cancer
cell lines revealed a profound downregulation of COBRA1 expression, which was
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accompanied by decreased cellular proliferation (Pohl, 2005). This finding was consistent
with another study done on Lung cancer (Sudhir et al., 2011).
All previous findings provide conflicting data regarding COBRA1 and suggest it having a
cancer-type dependent role, which in turn highlights the complexity of this molecule. As to
our knowledge, the role of COBRA1 in cervical cancer progression has not been studied
before.

HYPOTHESIS AND SPECIFIC OBJECTIVES
Previous studies on the role of COBRA1 in cancer progression have revealed a cancer-type
dependant role. It has been previously implicated in restraining breast cancer while
promoting UGCs development. Studies from our group indicated a potential role for
COBRA1 in HCC (El Zeneini et al., 2017; Youssef et al., 2016). Very little is known about
the role of COBRA1 in CC, hence we decided to extend the scope of our group’s research
from HCC to CC. We hypothesize that COBRA1 could be one of the players involved in the
pathogenesis of CC. To address this hypothesis, our study had the following four main
objectives:
1. In-silico analysis of the expression pattern of COBRA1 in cervical carcinoma versus
normal cervical tissues using online publicly available microarray database.

2. To achieve an efficient COBRA1 knockdown in the cervical cancer cell line, HeLa.
The HeLa cell line is an adenocarcinoma cell line derived from Ms. Henrietta Lacks,
a 31-years old African-American female. The cells have a characteristic cobblestonelike, epithelial appearance and has been reported to contain human papilloma virus
18 (HPV-18) sequences (Lucey, Nelson-Rees, & Hutchins, 2009).

3. To investigate the effect of COBRA1 Knockdown on cellular proliferation and
migration of HeLa.

4. To examine the expression pattern of NELF complex subunits and some cancer
related genes following COBRA1 silencing.
12

2. MATERIALS AND METHODS

2.1 Cell lines and culture
Human cervical adenocarcinoma cell line HeLa was grown in Dulbecco’s modified Eagle’s
medium (DMEM) (GIBCO, USA) supplied with 10% fetal bovine serum (GIBCO, USA),
100 U/ml penicillin and 100 mg/ml streptomycin (GIBCO, USA). Cells were maintained in
a humidified incubator supplied with 5% CO2 at 37 ̊Ϲ. In all below-described experiments,
cells in the logarithmic phase of growth from passage numbers 6-20 were used and
propagated at 70-80% confluency according to the American type culture collection
protocol. An inverted microscope (Olympus IX70, USA) was used to observe the cells.
HeLa cells doubling time has been found to be approximately 25 hrs.

2.2 Viable Cell Count
Trypan Blue exclusion method was used to obtain the viable cell count prior to each
experiment. Cells were harvested and re-suspended in fresh media by pipetting up and down
until a homogenous cell suspension with no cell clumps was obtained. Fifty microliters (µl)
from this cell suspension was mixed with 50 µl of 0.4% trypan blue in PBS. In each chamber
of a haemocytometer (Hausser Scientific, USA) 10 µl of the trypan blue-cell suspension was
loaded. The cells in each of the outer four squares in the two chambers were counted and
the following equation was used to calculate the number of cells per 1 ml of cells suspension:

Number of cells/ml = (Total numbers of viable cells in all counted squares / total number
of counted squares) x dilution factor x10000

2.3 RNA Interference
Silencing of COBRA1 (NCBI: NM_015456) was achieved by using siGENOME
SMARTpool (Dharmacon, M-015839-00). It is a pool of four different siRNAs targeting
different regions of COBRA1 mRNA. Table1 includes the siRNAs target sequences and
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corresponding exon locations of COBRA1. Other siRNAs used in this study include
GAPDH siRNA (SI02653266) and ALLStars Negative control siRNA (SI03650318), both
purchased from Qiagen. GAPDH siRNA was used as a positive control for the transfection
procedures and its efficiency in delivering the siRNAs into HeLa cells. ALLStars Negative
control siRNA has no homology to any known mammalian gene and it was used to control
for any nonspecific effects on gene expression and phenotype that can happen as a result of
the transfection procedure itself. All siRNAs were received as lyophilized powders and were
re-suspended in RNase-free water as per the manufacturers’ instructions to obtain working
solutions of final concentrations of 20 µM.

Table 1. COBRA siRNAs target sequences with their corresponding exons locations
siRNA

Target sequence

Target Exon

siGENOME

1

CCGAAAGCUUCACUAAGUU

9&10

SMARTPool

2

GCGACUUGGCCUUUGGCGA

11

M-015839-00

3

GAGCCUGGGACAUGAUCGA

8

4

CGUCUAAGCUGGAGGCGUU
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2.4 siRNA Transfection
An RNase-free environment was strictly maintained throughout all experimental
procedures. The transfection of siRNAs (COBRA1 siRNA, ALLStars Negative control
siRNA and GAPDH siRNA) into HeLa cells was performed in 6-well plates using
Lipofectamine 3000 (Life Technologies). The efficiency of Lipofectamine 3000 in HeLa
cells was assessed via forward transfection of 25nM of GAPDH siRNA for 72 hrs.
Transfection procedures were optimized regarding the transfection protocol (forward versus
reverse), siRNAs final concentration/well and duration of transfection. The following
optimized conditions were maintained in all experiments. Approximately 1.5 x 105 cells
were reverse transfected with 35 nM of siRNA using 3.75 µl of Lipofectamine 3000
according to the manufacturer’s protocol in a final volume of 2 ml/ well. In one well of a 6well plate, 3.5 µl of COBRA1 siRNA solution (20 µM) was mixed with 500 µl of low serum
opti-MEM media (Gibco). After 5 minutes, 3.75 µl of Lipofectamine was added to the well
and left for 15-20 minutes at room temperature to allow for the formation of siRNA- Lipid
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complex. Following this short incubation, 1.5 ml of HeLa cells suspension (approximately
1.5 x 105 cells) in antibiotic free complete DMEM media were added to the well. The same
procedures were repeated for the negative control siRNA. As additional controls, cells were
either left un-transfected (Untreated) or treated with Lipofectamine only (Mock). Cells were
maintained in culture for 72 hrs post transfection followed by harvesting for RNA and
protein analysis.

2.5 RNA Extraction
Trizol reagent (Invitrogen, USA) was used to extract total RNA from HeLa cells according
to the manufacturer's instructions. An RNase-free environment was maintained during all
extraction procedures. The extracted RNA was dissolved in nuclease-free water (Thermo
Scientific, USA). The concentration and purity of the RNA were measured at both 260 and
280 nm using a SPECTROstar Nano Absorbance plate reader (BMG Labtech). RNA
concentration was automatically computed by the devise using the following equation:
[RNA concentration (µg/ml) = OD at A260 x Dilution Factor x 40].

2.6 Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Semi quantitative RT-PCR was used to determine the differential gene expression at the
messenger RNA level (mRNA) among tested conditions. Total RNA (0.5 μg) was reverse
transcribed in a final volume of 20 µl using Revert Aid First strand cDNA synthesis Kit
(Thermo Scientific, USA) according to the manufacturer’s protocol.
All primers used for the amplification of the selected genes are listed in Table 2. PCR
amplifications conditions were programmed for 5 minutes at 94°C, followed by cycles of
(denaturation at 94ºC for 30 seconds, annealing at the specified temperature for each of the
used primers sets for 30 seconds, extension at 72ºC for 45 seconds) and ending the process
with 10 minutes at 72ºC. The PCR products were then separated on a 1.5 - 2 % agarose gel
depending on product size and visualized using Gel Doc EZ System (Bio-Rad, USA)
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Table 2. RT-PCR primer sequences, PCR amplification conditions and amplicon sizes (F:
forward primer, R: reverse primer, bp: base pair)
Gene

Primer Sequence

PCR

Amplicon

Condition

Size

s
GAPDH

β-ACTIN

F : 5’-CCACCCATGGCAAATTCCATGGCA-3’

60.5ºC

R: 5’-TCTAGACGGCAG GTCAGGTCCACC-3’

27 Cycles

F: 5’-GCAAAGACCTGTACGCCAAC-3’
R: 5’-GAGACCAAAAGCCTTCATACATCTC-3’

COBRA1

NELF-A

NELF-C/D

NELF-E

59.5ºC

R: 5’-GATCCAGCTGTTCCAGCTTC-3’

32 Cycles

F: 5’-GTCGGCAGTGAAGCTCAAGT-3’

60ºC

R: 5’-TTCACACTCACCCACCTTTTCT-3’

35 Cycles

F: 5’-GAAGAAGGAGAGACCCCAGC-3’

56 ºC

R: 5’-GTGCCCAAGGCTAGTGTGAT-3’

28 Cycles

F: 5’-TGGTGAAGTCAGGAGCCATCAG-3’

β-catenin

survivin

777bp

27 Cycles

F: 5’-ACATCACCAAGCAGAGGAA-3’

R: 5’-CGCCGTTCAGGGAATGAATC-3’
Ki67

58ºC

598 bp

63 ºC

366 bp

250 bp

443 bp

565 bp

28 Cycles

F: 5’-CTTTGGGTGCGACTTGACG-3’

60 ºC

R: 5’-GTCGACCCCGCTCCTTTT-3’

28 Cycles

F: 5’-ACTGGCAGCAACAGTCTTACC-3’

61 ºC

R: 5’-TTTGAAGGCAGTCTGTCGTAAT-3’

30 Cycles

F: 5’-TTGAATCGCGGGACCCGTTGG -3’

61 ºC

R: 5’-CAGAGGCCTCAATCCATGGCA-3’

28 Cycles

199 bp

837 bp

Isoform 1:
477 bp
Isoform 2:
359bp
Isoform 3:
546bp

TFF1

F: 5’-TTTGGAGCAGAGAGGAGGCAATGG-3’
R: 5’-TGGTATTAGGATAGAAGCACCAGGG-3’

64 ºC

240 bp

32 Cycles
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2.7 Western Blot Analysis
Cells were harvested at the specified time point and washed with ice cold PBS before they
were lysed in 1X ice-cold Laemmli Lysis Buffer (50mM Tris Ph6.8, 2% sodium dodecyl
sulphate (SDS) and 10% glycerol). For each 1 ml of Lysis buffer, 10 µl of 100X Halt
Protease Inhibitor Cocktail (ThermoScientific, USA) was added. Cells in Lysis buffer were
incubated at 4°Ϲ for 40 minutes with vortexing at 10 minutes intervals followed by
centrifugation at 14000 rpm and 4°Ϲ for 15 minutes. Supernatants were collected and were
used to determine protein content using BCA Protein Assay Kit (Pierce Biotechnology,
USA) according to the manufacturer’s protocol.
Equivalent amounts (20-40 μg) of proteins diluted in lysis buffer were mixed with 4X
loading dye (60% Glycerol, 360 mM Tris-HCl pH 6.8, 12% SDS, 0.06% bromophenol blue,
30% beta-mercaptoethanol) in a final volume of 28 µl. Samples were boiled at 100°Ϲ for 5
minutes prior to being loaded onto a 12 % SDS-polyacrylamide gel and separated by
electrophoresis at 120V. Consequently, they were blotted to a nitrocellulose membrane (GE
Healthcare). Blotted membrane was blocked with 5% non-fat dry milk in 1X TBST (0.01%
Tween-20 in TBS) at room temperature for 2 hrs, after which the membrane was incubated
with primary antibodies at 4 ºC overnight. Following three times washing (5 minutes each)
with the wash solution (1 X TBS with 0.01% Tween), the membrane was incubated with
alkaline phosphatase conjugated secondary antibody (either goat anti-rabbit IgG (KPL) or
goat anti-mouse (KPL) diluted as 1:20,000 in 5% non-fat milk) at RT for 2 hrs. Three times
of washing to remove excess secondary antibody with the wash solution was performed. For
detection, the membrane was incubated with chromogenic substrate BCIP/NBT (KPL) until
signals became visible with naked eye. Anti-GAPDH (Abcam, ab8245) (1:10,000 in 5%
non-fat dry milk), Anti-β-tubulin (Sigma, T7816) (1:20,000 in 5% non-fat dry milk) and
anti-COBRA1 (Abcam, ab167401) (1:1000 in 3% non-fat dry milk) were used as primary
antibodies in this study.
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2.8 MTT Assay
The effect of COBRA1 silencing on the viability and proliferation of HeLa cells was
analysed by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay
as previously described (Chai & Yang, 2014; Yang et al., 2009; K. Zhu, Chen, Han,
Wang, & Wang, 2012). Briefly; for reverse transfection in 96 well plates, 0.175 µl of the
20 μM siRNA solutions and 0.15 µl Lipofectamine 3000 were diluted with 20 µl opti-MEM
media and mixed with 6000 cells suspended in 80 µl antibiotic free complete DMEM media
to reach a final concentration of 35 nM of siRNAs/well. Cells were maintained in culture
for 72h, after which media was replaced with 100 µl of fresh opti-MEM and 10 µl of 5
mg/ml MTT solution (Serva) was added to each well. The cells were incubated for 3 hr,
media with MTT removed and the resulting intracellular purple formazan was solubilized
using 100 μl of dimethylsulphoxide (DMSO, Sigma). Cells were incubated with DMSO for
5-10 min, then shacked for 2 min in dark. Absorbance was measured at 490 nm using
SPECTROstar Nano microplate reader (BMG Labtech). The assay was run in triplicates for
each condition (Untreated cells, Mock-treated, Negative siRNA and COBRA1 siRNA
treated cells). Three control wells of used medium alone were used to provide the blanks for
absorbance readings. The average of the obtained triplicate absorbance readings for each
tested condition was used to calculate percentage cell viability as follows;
Percentage Cell Viability = (Absorbance of Test/ Absorbance of Control) x 100

2.9 Wound Healing Assay
The scratch wound healing assay was used to investigate differences in cell migration
abilities that might occur as a result of COBRA1 silencing in HeLa cells. The assay was
performed as previously described (El Zeneini et al., 2017; Youssef et al., 2016). In brief,
reverse transfection of COBRA1 siRNA into HeLa cells was carried out in 12 well plate.
Approximately 7.5 x 104 cells were reverse transfected with 35nM 0f siRNA using 1.5 μl
of Lipofectamine 3000 according to the manufacturer’s protocol in a final volume of 1ml.
At 72 hours post-transfection, the cell monolayer was carefully scraped using a sterile 20 μl
pipette tip, once vertically and once horizontally creating a cross in the center of each well
(0 hr). Floating cells were removed by washing with media. Cells were monitored for
additional 24 hours (24 hrs). Images were taken using phase contrast at 10X magnification
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power at 0 hr and 24 hrs. The wound area was analysed using ImageJ software and
percentage wound closure was calculated as follows:
Percentage wound closure = [(Wound area0h-Wound area24h)/Wound area0h] x 100

2.10 Data Mining
The Oncomine cancer microarray database and integrated data-mining platform
(http://www.oncomine.org/, last accessed April 2018) (Rhodes et al., 2004) was used to
investigate the expression profile of COBRA1 mRNA in cervical carcinoma versus
respective normal samples. The used filter criteria included COBRA1 gene in cancer versus
normal analysis, cancer type was restricted to cervical cancer and data type was limited to
mRNA microarrays. Statistical significance was automatically computed by the default
Oncomine algorithms using a two-tailed Student’s t-test. Table 3 includes cervical cancer
microarray datasets utilized in this study.
The Human protein Atlas (https://www.proteinatlas.org/, last accessed April 2018) was used
to query the expression pattern of COBRA1 in HeLa relative to other cervical carcinoma
cell lines, in addition to HepG2 cells previously used by our group for COBRA1 silencing.

2.11 Statistical Analysis of Data
Image J software (National Institute of Health, USA, http://www.imagej.nih.gov/ij) was
used for quantifying the bands intensities for PCR and Western Blot analyses. Bands were
quantified and normalized per the used internal control. Relative differences in gene
expression are described as fold change relative to negative siRNA transfected cells unless
specified otherwise. Statistical analyses and graphical representations were performed using
GraphPad Prism 5.0 (GraphPad, San Diego California USA, http://www.graphpad.com/).
All the data represent the average ± standard deviation (SD) from three independent
experiments unless specified otherwise. One-way ANOVA, followed by a Bonferroni posthoc test, was used to determine the statistical significance among multiple different
experimental groups in case of single variable. For comparisons made between two different
groups, statistical significance was assessed using an unpaired student's t-test (two-tailed).
P–value less than 0.05 was considered to be statistically significant (* p <0.05, ** p <0.01,
*** p <0.001).
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Table 3. Oncomine Microarray datasets utilized to query the expression profiles of
COBRA1 in cervical carcinoma compared to normal cervix samples.

Study

Total No. of

Type of sample

Number of

Samples/Microarray

Scotto

66

Cervix 2

Reference

samples/Type
•

Normal Cervix

24

Scotto et

•

Cervical

32

al., 2008

Squamous Cell
Carcinoma

Pyeon

84

Multi-

•

Normal Cervix

8

Pyeon et

•

Cervical Cancer

20

al., 2007

•

Normal Cervix

10

•

Cervical

cancer

Zhai

41

Cervix

Zhai et al.,

Squamous Cell

21

2007

Carcinoma
•

High

Grade

7

Cervical
Squamous
Intraepithelial
Neoplasia

Biewenga
Cervix

45

•

Normal Cervix

5

Biewenga

•

Cervical

40

et al.,

Squamous Cell

2007

Carcinoma
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3. RESULTS

3.1 Expression of COBRA1 mRNA in cervical cancer tissues relative to
normal cervical tissues
Publicly available microarray datasets in the Oncomine Cancer Microarray database were
queried to investigate the expression pattern of COBRA1 in cervical cancer versus normal
counterparts at the RNA level. The search yielded results from four different datasets, from
four independent studies (Biewenga et al., 2008; Pyeon et al., 2007; Scotto et al., 2008;
Zhai et al., 2007). As shown in Figure 1, COBRA1 was found to be significantly
overexpressed in cervical cancer relative to normal cervix tissues in each of the Scotto
Cervix and Pyeon multi-cancer studies with a fold change between 1.2 - 1.8 (p<0.05). In
Zhai Cervix dataset, COBRA1 was found to be slightly higher than normal with a fold
change of 1.022 but with a statistically non-significant p-value (p>0.05). On the contrary, in
Biewenga cervix, COBRA1 was shown to be downregulated relative to normal tissues, but
again this was found to be statistically non- significant (p>0.05).
Results obtained from Human Protein Atlas (HPA) revealed comparable expression pattern
of COBRA1 in each of HeLa (cervical adenocarcinoma), SiHa (cervical squamous
carcinoma) and HepG2 (Liver cancer) cell lines. HPA results are represented as the
transcript abundance for each protein-coding gene. It is worth mentioning that HepG2 was
previously used by our group for successful silencing of COBRA1. Since successful siRNA
mediated knockdown depends; among other factors, on target gene abundance (Hong,
Jiang, Kim, Li, & Lee, 2014), HPA results suggested that HeLa could serve as a suitable
model for COBRA1 silencing (Figure 2).

3.2 Knockdown of COBRA1 in CC cell line, HeLa
Based on the finding of an upregulated expression pattern for COBRA1 in CC observed
from our in silico studies, we hypothesized that COBRA1 could have a role in CC
tumorigenesis. Hence, we analysed the effect of COBRA1 gene silencing via siRNAmediated RNA interference (RNAi) in HeLa cells. For achieving an efficient siRNA
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Figure 1. Overexpression of COBRA1 in cervical carcinoma tissues versus normal samples.
Publicly available microarray data in OncomineTM cancer database was searched to examine the
expression of COBRA1 in cervical carcinoma versus normal cervix samples. Four datasets from 4
independent studies were analysed. A] Studies showing significant overexpression of COBRA1 in
cervical carcinoma B] Study showing slightly higher COBRA1 expression but statistically nonsignificant. C] Study showing downregulation in COBRA1 expression. OncomineTM results are
illustrated as boxplots, with the top and bottom of the box representing the upper and lower quartiles,
respectively and the bar across the box, the median. The bars represent the 10th and 90th percentile
and dots represent the minimum and maximum values within each category. Number of patients in
each category (n), fold change and P-value are indicated for each study ** P<0.01, *** P<0.001. In
Scotto Cervix, normal samples included 21 normal cervix tissue specimens and 3 commercial RNA
from cervix uteri.
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Figure 2. The abundance of COBRA1 in cancerous cell lines. Human protein Atlas was queried
to investigate the abundance of COBRA1 mRNA in HeLa cells compared to SiHa and HepG2 cancer
cell lines. The RNA-sequencing results generated in the HPA are reported as the number of
Transcripts per Million (TPM) of the total protein-coding transcripts.

mediated transient knockdown, optimization of the transfection protocol regarding
efficiency of Lipofectamine 3000 in HeLa cells, siRNA concentration, transfection method
and transfection duration had to be first performed according to the manufacturers’
protocols. This optimization process was aimed at obtaining the highest possible knockdown
efficiency at the COBRA1 protein and mRNA levels, with minimal effects on cell viability.

3.2.1 Lipofectamine 3000 knockdown efficiency in HeLa cells
To investigate the possibility of performing COBRA1 knockdown using Lipofectamine
3000 reagent, knockdown of the house-keeping gene GAPDH with 25 nM of GAPDH
specific siRNA using 3.75 µl Lipofectamine 3000 was first performed via forward
transfection protocol. Cells were harvested 72 hrs post-transfection and results were
evaluated at the mRNA level by semi-quantitative RT-PCR. As shown in Figure 3,
Lipofectamine 3000 resulted in ≈ 80 % silencing of GAPDH mRNA relative to the negative
control.
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Figure 3. Knockdown of GAPDH in HeLa cells using Lipofectamine 3000. RNA expression was
analysed by semi-quantitative RT-PCR. Band intensities were quantified by ImageJ and normalized
to the internal control β-ACTIN. Relative expression is expressed as fold change to siNTC.
siGAPDH: GAPDH siRNA, siNTC: Negative siRNA.

3.2.2 SiRNA Concentration
Different concentrations of siRNAs within the range recommended by the supplier; 25 nM,
35 nM, and 45 nM, were tested using forward transfection protocol. Knockdown efficiency
was assayed 72 hrs following transfection by semi-quantitative RT-PCR and Western Blot.
As shown in Figure 4, transfecting the cells with a final concentration of 35 nM COBRA1
siRNA/well resulted in achieving a knockdown of ≈90% at the mRNA level and the highest
observed knockdown of ≈80% at the COBRA1 protein level. Hence, the 35 nM
concentration was used for all subsequent siRNA transfections. Cell viability and
morphology were observed by phase contrast microscopy 10X and were found to be
comparable in all siRNAs treated, mock-treated and untreated cells with the volume of
Lipofectamine used (3.75 µl).
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Figure 4. Optimization of siRNA concentration via forward transfection. A) RNA expression
was analysed by semi-quantitative RT-PCR. Band intensities were quantified by ImageJ and
normalized to the internal control β-ACTIN. B) Protein expression analysed by Western Blot. Band
intensities were quantified by ImageJ and normalized to the internal control β-TUBULIN. Relative
expression is expressed as fold change to siNTC. siCOBRA1: COBRA1 siRNA, siNTC: Negative
siRNA.

3.2.3 Transfection Method
Successful gene silencing in siRNA-mediated RNA interference (RNAi) experiments
requires efficient uptake of siRNA into the cells. Two variations of transfection were tested:
standard forward and reverse transfections. They mainly differ in the order and timing of the
addition of the three necessary components of transfection: siRNA, lipid-based transfection
reagent, and cells. In forward transfection, siRNA and Lipofectamine reagent are complexed
in low serum media and added to pre-seeded cells that are 70-80% confluent. In reverse
transfection, all three components are added to the wells at essentially the same time.
Reverse transfection reduces the time for transfection by one day compared to forward
transfection. As shown previously (Figure 4), forward transfection of HeLa cells with 35
nM COBRA1 siRNA resulted in ≈ 80% knockdown on the COBRA1 protein level. For the
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aim of selecting the method that could achieve the highest possible depletion Of COBRA1
protein, reverse transfection method was performed and the transfection efficiency between
both the reverse and forward transfections was compared. As shown in Figure 5, 72 hr posttransfection, the reverse transfection resulted in a higher efficiency (93%) than that observed
with the forward transfection. Accordingly, the reverse transfection protocol together with
the 35nM concentration of siRNAs was used in the subsequent transfection experiments.

3.2.4 Knockdown Duration
The siRNA mediated COBRA1 used in this study cause transient silencing of the expression
of the target gene. To identify the optimum time point at which maximum knockdown of
the effective protein levels occurs, knockdown efficiency was analysed at 24 hr, 48 hr and
72 hr post-transfection by Western Blot and RT-PCR. As shown in Figure 5, incubating the
cells for 72 hrs resulted in the highest silencing effect (93%) at the COBRA1 protein level,
compared to (86%) at 48 hrs and (28%) at 24 hrs. On the other hand, the highest knockdown
at the mRNA level (94.2%) was observed at 24 hrs post transfection compared to ≈ 80% at
72 hrs. Since the goal is achieving an efficient knockdown at the protein level, all subsequent
siRNA transfections in the HeLa cell line were performed at 72 hrs.

3.3 COBRA1 SMARTPool siRNA Knockdown efficiency in HeLa cells
To confirm the efficiency of SMARTPool siRNA in HeLa cells, transfection was repeated
using the finally chosen optimized conditions; reverse transfection, 35Nm siRNA, 72 hrs
and 3.75 μl Lipofectamine 3000. The expressions of COBRA1 mRNA and protein levels
were assessed post-transfection in each of the tested groups by semi-quantitative RT-PCR
and Western Blot respectively. Figure 6 shows that both mRNA and protein levels were
significantly down regulated in COBRA1 siRNA HeLa treated cells compared to the
Negative siRNA treated and the untreated cells. Data from three independent experiments
were collected and statistical significance was computed. The COBRA1 silencing effect was
found to be ≈ 79% at the mRNA levels (P<0.01) and 95.5% at the protein level (P<0.001).
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It is worth mentioning that the COBRA1 knockdown did not have any significant impact on
the overall cellular morphology of HeLa cells as observed under the inverted microscope
(10X) when compared to the untreated or negative siRNA treated cells (Figure 7).

A

B

Figure 5. Optimization of knockdown duration via reverse transfection. Knockdown efficiency
was analysed at 24, 48 and 72 hours post-transfection. A) RNA expression was analysed by semiquantitative RT-PCR. B) Protein expression analysed by Western Blot. Bands intensities were
quantified by ImageJ and normalized to the internal control GAPDH. Relative expression is
expressed as fold change to siNTC. siCOBRA1: COBRA1 siRNA, siNTC: Negative siRNA.
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Figure 6. COBRA1 SMARTPool siRNA effectively silences COBRA1 expression using the
optimized transfection conditions. A) mRNA expression was analysed by semi-quantitative RTPCR. B) Protein expression analysed by Western Blot. Bands intensities were quantified by ImageJ
and normalized to the internal control GAPDH. Relative expression is expressed as fold change to
siNTC. Data represent the means ± SD of three independent experiments (n=3). Statistically
significant at **p<0.01, ***p<0.001(one-way ANOVA, Bonferroni’s post-test (A) and unpaired
Student’s t-test, two tailed (B)). siCOBRA1: COBRA1 siRNA, siNTC: Negative siRNA.
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Figure 7. Morphological examination of HeLa cells post-transfection. Photos were taken with 10X
magnification power at 24, 48 and 72 hours post-transfection. Cells were either reverse transfected with
COBRA1 siRNA or Negative siRNA. As control, cells were left untreated

3.4 Effect of COBRA1 silencing on the expression patterns of NELF complex
subunits
The mRNA expression levels NELF-A, NELF- C/D and NELF-E subunits were analysed
using semi-quantitative RT-PCR in all of the tested conditions (Untreated and Negative
siRNA compared to COBRA1 siRNA transfected cells). It was found that none of the other
three subunits was affected by COBRA1 (NELF-B) knockdown and there was no
statistically significant difference at the mRNA expression level among any of the tested
conditions (P> 0.05) (Figure 8).

Figure 8. COBRA1 silencing does not alter the mRNA steady-state expression of other NELF
complex subunits. NELF-A, NELF-C/D and NELF-E RNA expression was analysed by semiquantitative RT-PCR 72 hrs post-transfection in each of the tested groups. Bands intensities were
quantified by ImageJ and normalized to the internal control GAPDH. Relative expression is
expressed as fold change to siNTC. Data represent the means ± SD of three independent experiments
(n=3). Results were found to be statistically non-significant at p>0.05 (one-way ANOVA,
Bonferroni’s post-test). siCOBRA1: COBRA1 siRNA, siNTC: Negative siRNA.
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3.5 COBRA1 Silencing effect on the proliferation of HeLa cells
The effect of COBRA1 on cellular proliferation was first examined via the methyl
tetrazolium (MTT) assay. Reverse transfection of HeLa cells with 35 nM of either the
COBRA1 siRNA or Negative siRNA using Lipofectamine 3000 was performed in 96 well
plates according to the manufacturers’ protocols. Percentage cell viability was used as an
indication for the cellular proliferation. As shown in Figure 9A, there was a statistically
significant decrease in the cellular proliferation of the COBRA1 siRNA treated cells
compared to the untreated and mock controls but not to the negative siRNA treated cells.
Further investigation of the effect of silencing on HeLa cells proliferation was done by
examining the expression profile of Ki-67, an important marker for cellular proliferation.
Ki-67 protein is absent in the resting phase of cell cycle (G0) while it is present in all active
phases (G1, S, G 2, and mitosis) proving that its expression is essential for cell cycle
progression (Scholzen & Gerdes, 2000). In accordance with the previous results from the
MTT assay, no statistically significant difference in the mRNA level of Ki-67 was observed
compared to the negative control but there was significant decrease compared to the
untreated cells (Figure 9B).

3.6 COBRA1 Silencing effect on the migration potentials of HeLa cells
The classical wound healing assay was used to investigate the effect of COBRA1 silencing
on the migratory potential of HeLa cells (El Zeneini et al., 2017; Youssef et al., 2016). The
cell monolayer was scratched post-transfection at the optimum knockdown time point (72
hrs) and images at this initial timing were compared to those taken after 24 hrs (Figure 10
A). Wound areas were analysed using ImageJ software and percentage wound closure was
calculated based on the given areas. Results have shown that there was no statistically
significant difference in the wound closure ability among tested conditions (p>0.05; Figure
10 B). The COBRA1 knockdown cells showed approximately 49.7 % wound closure after
24 hrs and the untreated, Mock-treated and siNTC treated cells showed 49.74%, 50.8% and
56.14 % wound closure respectively.
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Figure 9. Effect of silencing of COBRA1 on HeLa cells proliferation. A) MTT assay was used to
analyse the viability of HeLa cells following COBRA1 knockdown compared to the control groups.
B) RT-PCR of the proliferation marker Ki-67. Bands intensities were quantified by ImageJ and
normalized to the internal control GAPDH. Relative expression is expressed as fold change to
siNTC. Data represent the mean ± SD of three independent experiments (n=3). Statistically
significant at *p<0.05, **p<0.01 (one-way ANOVA, Bonferroni's post-test). siCOBRA1: COBRA1
siRNA, siNTC: Negative siRNA.
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Figure 10. Effect of silencing of COBRA1 on HeLa cells migration. Wound healing assay was
used to analyse the migration rate of HeLa cells following COBRA1 knockdown. A) Images of the
wound areas taken at 0 and 24 hrs times using phase contrast microscopy at 10X magnification. B)
Bars are representing Percentage of wound closure in each of the tested conditions. The open areas
were measured using ImageJ software followed by the calculation of the percentage of wound
closure. Data represent the mean ± SD of two independent experiments (n=2). (one-way ANOVA,
Bonferroni's post-test) (P>0.05). siCOBRA1: COBRA1 siRNA, siNTC: Negative siRNA.
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3.7 COBRA1 Silencing effect on some cancer related genes
The differential expression of a number of genes that have been previously reported to be
commonly deregulated in cancer were examined at the mRNA level post COBRA1 siRNA
transfection.
3.7.1 β- Catenin
Recent studies has suggested the Wnt/β-catenin signalling pathways as one of the pathways
involved in CC (Pérez-Plasencia et al., 2008). Semi-quantitative RT-PCR was carried out
to examine the mRNA expression of the β-catenin gene following COBRA-1 silencing. As
shown in Figure 11A, upon COBRA1 knockdown, there was a significant decrease in the
mRNA levels of β-catenin in COBRA1 siRNA treated cells relative to the negative control.
3.7.2 Survivin
Survivin is one of the genes known to be commonly deregulated in cancer (Garg, Suri,
Gupta, Talwar, & Dubey, 2016; Jaiswal, Goel, & Mittal, 2015). RT-PCR was carried
out to examine the mRNA expression of the survivin gene following COBRA-1 silencing.
As shown in Figure 11B, upon COBRA1 knockdown , there was an observable decrease in
the levels of each of the three detected isoforms of survivin (survivin-2B, survivin-DeltaEx3
and the wild-type survivin) but it was found to be statistically significant only in survivin2B and survivin-DeltaEX3 isoforms levels compared to the negative control group with a
p-value<0.05.
3.7.3 TFF1
TFF1 is one of a family of highly conserved, secreted trefoil peptide proteins. It has been
previously reported that TFF1 expression is negatively regulated by the NELF complex in
breast cancer (Aiyar et al., 2004; Aiyar, Cho, Lee, & Li, 2007). In upper gastrointestinal
tract cancers (UGC), overexpression of COBRA1 was associated with down regulation of
TFF1 (McChesney et al., 2006). To determine the effect of silencing COBRA1 on the
mRNA levels of TFF1, semi-quantitative RT-PCR was performed. As shown in Figure 12,
there was a statistically significant increase in the TFF1 levels following COBRA1 siRNA
transfection compared to the negative siRNA treated cells (p <0.001).
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Figure 11. Effect silencing of COBRA1 on the expression of B-catenin and survivin. A) Effect
of COBRA1 knockdown on β-catenin. B) Effect of COBRA1 knockdown on survivin. mRNA
expression was analysed by semi-quantitative RT-PCR. Bands intensities were quantified by ImageJ
and normalized to the internal control GAPDH. Relative expression is expressed as fold change to
the siNTC. Data represent the mean ± SD of 2 independent experiments (n = 2). Statistically
significant at *p < 0.05 (unpaired Student t-test, two tailed). siCOBRA1: COBRA1 siRNA, siNTC:
Negative siRNA.
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Figure 12. Effect of silencing of COBRA1 on the expression of TFF1. Effect of COBRA1
knockdown on TFF1 mRNA levels was analysed by semi-quantitative RT-PCR. Bands intensities
were quantified by ImageJ and normalized to the internal control GAPDH. Relative expression is
expressed as fold change to the siNTC. A significant upregulation was observed in the expression of
TFF1 following COBRA1 knockdown, relative to siNTC treated group. Data represents the mean ±
SD of 2 independent experiments (n = 2). Statistically significant at *** p < 0.001 (one-way
ANOVA, Bonferroni’s post-test). siCOBRA1: COBRA1 siRNA, siNTC: Negative siRNA.
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4. DISCUSSION
Cervical carcinoma (CC) is the fourth leading cause of cancer-related deaths among women
worldwide and the second most commonly diagnosed cancer in developing countries,
accounting for an estimated 527,600 new cervical cancer cases and 265,700 deaths
worldwide in 2012 (Torre et al., 2015). Improved understanding and increased knowledge
of the molecular biology events associated with cervical carcinogenesis will help in
developing more specific biomarkers and targeted therapeutics for better control of CC.
Cofactor of BRCA1 (COBRA1) has been shown to be involved in many types of cancers
with previous studies by our group have identified a potential role for COBRA1 in HCC
progression (El Zeneini et al., 2017; Youssef et al., 2016). In this study, we extended the
scope of our group’s research to investigate the possibility of COBRA1 having a potential
role in CC as previously detected in HCC. This was performed through analysing the
consequences of COBRA1 Knockdown on the cellular behaviour of HeLa cells and on the
expression pattern of some cancer-related genes.

4.1 Data mining results
To explore the expression pattern of COBRA1 in cervical cancer, analysis of the microarray
data publicly available on the Oncomine cancer microarray dataset was first performed. The
used search filter criteria resulted in the identification of four datasets from four different
independent studies; Pyeon Multi-cancer, Scotto Cervix 2, Zhai Cervix and Biewenga
Cervix (Biewenga et al., 2008; Pyeon et al., 2007; Scotto et al., 2008; Zhai et al., 2007).
These studies were directed at investigating different aspects related to cervical cancer. The
Scotto Cervix study mainly aimed at identification of the genetic expression profiles
associated with the gain in long arm of chromosome 20 in various stages of progression of
CC [Stages Ⅰ, Ⅱ, Ⅲ and Ⅳ]. Pyeon Multi-cancer study goal was defining similarities and
differences of HPV-positive versus HPV-negative cancers arising in the same tissue, this
study included samples for head and neck cancers in addition to cervical cancers [FIGO
stage IB (80%), II/III (15%) and IV (5%)]. The Zhai cervix study aim was to test differential
genetic expression profiles in human pre-invasive, invasive cervical squamous cell
carcinomas and normal cervical epithelia, the stages of disease for the tumor specimens used
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were not specified. As for Biewenga cervix study, its main objective was first to test whether
there is a differential gene expression profile for early stage cervical cancer tumours [FIGO
stage ⅠB1, ⅠB2 and ⅡA] with and without lymph node metastasis, as a means for predicting
the presence of lymph node metastasis before treatment. Subsequently, the authors
compared gene expression profiles between healthy cervical tissue and early stage cervical
cancer tissue.
In two of these studies, Scotto Cervix and Pyeon multi-cancer, COBRA1 mRNA was found
to be significantly overexpressed in CC tissues versus normal with a fold change of 1.245
(p= 0.003) and 1.76 (p=2.81E-4) respectively. As for Zhai cervix study, COBRA1 was found
to be slightly upregulated with a fold change of 1.066 but this was found to be statistically
insignificant (p=0.121). In contrast to the first three studies, in the Biewenga Cervix study
COBRA1 was found to be downregulated with -1.1441 fold change but again this was found
to be insignificant with a very high p-value of 0.999.
The observed variations in microarrays data might be referred to differences in the
experimental factors associated with each study. This could include variations in samples
handling, RNA handling, used microarray platforms, probes sequences and differences in
used computational methods for data analysis and validation. It is worth noting that in each
of the Pyeon Multi-cancer, Scotto cervix and Zhai Cervix studies, studies used
microdissection to enrich for the epithelial tumor cells before RNA extraction for microarray
analysis, while in Biewenga RNA was extracted from tissues of samples having >70%
tumors thus including normal cells in addition to the cancerous ones. In addition each of the
first three studies Affymetrix U133A oligonucleotide microarrays were used (containing the
whole genome, 14,500 and 22,283 probe sets respectively), while in Biewenga the whole
genome human oligonucleotide microarrays (44K Agilent) were used. The staging of the
tumors also might contribute to the results. In each of Pyeon multi-cancer and Scotto Cervix,
samples included in the microarray analysis represented different stages of CC [Stages Ⅰ, Ⅱ,
Ⅲ and Ⅳ]. On the other hand, Biewenga Cervix focused on early stages of CC [stages Ⅰ and
Ⅱ]. Tumor stages were not specified in Zhai Cervix and were referred to collectively as being
invasive cervical cancers.
Altogether, the in-silico analysis results suggests that there is an overexpression pattern for
COBRA1in CC. Further meta-analysis of these datasets will help gain more necessary
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information through correlating COBRA1 expression with the clinic-pathological features
as the HPV-subtype, stage and size of the tumor and treatment outcome.

4.2 Expression of NELF complex subunits
The assembly of the four subunits of the NELF complex (NELF-A, NELF-B, NELF-C/D
and NELF-E) is required for the formation of a functional complex. The core of the complex;
which consists of NELF-B (COBRA1) and NELF-C/D, binds each of the NELF-A having
the RNAPⅡ binding domain and NELF-E having the RNA binding domain (Narita et al.,
2003). This interdependent nature of the NELF subunits was reported in 2004 by Aiyar et
al., where the binding of the COBRA1 to the activated ERα was followed by the recruitment
of the other NELF subunits and the formation of a functional NELF complex at the
promotors of estrogen responsive target genes (Aiyar et al., 2004).
In this study, the knockdown of COBRA1 had no effect on the expression pattern of the
other NELF subunits at the mRNA level. This goes in accordance with previous results from
studies done on HCC by our group (El Zeneini et al., 2017) and other groups on UGC and
breast cancer (McChesney et al., 2006; Sun et al., 2008). It has been previously reported
that the depletion of one or more subunits of the NELF complex affects the other subunits
at the protein level (Aiyar et al., 2004; Kininis, Isaacs, Core, Hah, & Kraus, 2009; Sun
et al., 2008), which suggests the presence of post-transcriptional regulatory mechanisms that
governs the interdependent expression of NELF subunits . It will be interesting to further
investigate the protein levels of other subunits using Western Blot following silencing of
COBRA1 in HeLa cells to confirm this interdependency in cervical cancer.

4.3 Effect on HeLa cells proliferation and migratory abilities
The ability of cancer cells to maintain a state of chronic proliferation and to metastasize
from their initial primary tumor sites to secondary locations within the human body are
considered to be main hallmarks of cancer (Hanahan & Weinberg, 2011). Previous studies
related to COBRA1 and its role in cellular proliferation show some conflicting results. In
2004, Aiyar et al. research using breast cancer cells postulated a role for COBRA1 as an
inhibitor of estrogen mediated growth of T47D cancer cells (Aiyar et al., 2004). On the
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other hand COBRA1 has been found to support the proliferation of HCC with results
showing decreased cell count and Ki-67 mRNA expression in HepG2 cells upon depletion
of COBRA1 compared to negative control (El Zeneini et al., 2017).
In the present study, the role of COBRA1 in HeLa cells proliferation has been investigated
post-transfection first by measuring cell viability using MTT assay and second by examining
the expression pattern of the cellular proliferation marker Ki-67 at the mRNA level across
different tested groups. Even though there was a significant difference in percentage cell
viability of the COBRA1 siRNA treated cells compared to the untreated (p<0.05) and mocktreated cells (p<0.01), there was no significant difference in cell viability when compared to
the Negative siRNA treated cells. These results were also reflected at the Ki-67 levels, where
there was a significant difference in the expression between the untreated cells compared to
the siRNA treated cells but again no significant difference was observed in the COBRA1
siRNA relative to the negative siRNA treated cells. This decrease might be attributed to the
effects on cell viability that are known to be associated with the transfection process and not
due to the knockdown of COBRA1 itself.
It is important to mention that under the applied experimental conditions in this study, no
exogenous estrogen was supplied to any of the tested groups. Growing body of evidences
suggests a role for estrogen in the development of cervical carcinogenesis. Studies done on
HPV transgenic mice revealed that despite the fact that those mice could develop
spontaneous tumors, mainly in the skin, they rarely develop cervical cancers spontaneously
except when they are treated with exogenous 17 β-estradiol (S. Chung et al., 2010). In
accordance, the findings of a recent study in 2017 showed that estradiol could enhance the
proliferation and inhibit the apoptosis of Hela cervical adenocarcinoma cell line (Liu, Tian,
Yang, & Zhang, 2017). Hence, no conclusive results can be obtained from our findings
with regard to the role of COBRA1 in HeLa cells proliferation unless the transfection was
further performed with exogenous estrogen added to the media.
Regarding the effect of COBRA1 silencing on the migratory abilities of HeLa cells post
COBRA1 siRNA silencing, no significant differences in the percentage wound closure
across 24 hrs interval were noticed among any of the tested groups. This suggests that the
effect of COBRA1 with respect to proliferation and migration of HeLa cells might be
governed by the same above mentioned stimulus.
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4.4 Effect on mRNA expression level of TFF1
TFF1 (also known as pS2) is one of a family of highly conserved, secreted trefoil peptide
proteins. It is expressed mainly in the gastric epithelium as a component of the mucus layer
protecting the stomach against mucosal injury (Soutto et al., 2015). Initially, TFF1 was
found to be one of the estrogen inducible genes in the breast cancer cell line MCF7
(Masiakowski et al., 1982). In 2002, a study by Leung et al. suggested that there was a
gradual loss of TFF1 expression along the process of gastric tumorigenesis (Leung et al.,
2002).
It has been previously reported that TFF1 expression is negatively regulated by COBRA1
in both breast cancer and upper gastrointestinal tract cancers (Aiyar et al., 2004, 2007;
McChesney et al., 2006)
Notably, Aiyar et al., studies in breast cancer cell line T47D have shown that COBRA1
causes RNAPⅡ pausing at the promoter proximal regions of TFF1 in response to the liganddependent activation of ERα (Aiyar et al., 2004). This was contradictory to the results
obtained by Kininis et al., 2009 in MCF7 cells where the depletion of COBRA1 did not alter
the expression of TFF1 suggesting a cell-type specific effect for COBRA1(Kininis et al.,
2009).
In this study, examining the TFF1 mRNA levels in HeLa cell line upon COBRA1 silencing
revealed an inverse correlation between COBRA1 and TFF1. There was a significant
increase in TFF1 expression in COBRA1 siRNA treated cells compared to the negative
siRNA treated cells (p<0.001). This finding suggests that COBRA1 negatively regulates
TFF1 in HeLa cells as was previously reported in breast and UGCs.

4.5 Effect on mRNA expression level of β-catenin
Wnt/β-catenin signaling is involved in the control of a number of biological processes as
cellular proliferation, fate specification, migration, cell adhesion, tissue architecture, and
organogenesis. After Wnt couples to its receptors, one of the pathways that becomes
activated is the canonical pathway which induces the entry of β-catenin to the nucleus where
it acts by affecting the transcription of target genes (Pérez-Plasencia et al., 2008). Recent
studies have suggested the Wnt/β-catenin signaling as one of the main pathways deregulated
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in CC (Kwan et al., 2013; Pérez-Plasencia et al., 2008). Aberrant activation of Wnt/βcatenin signaling is mainly caused by the accumulation of β-catenin, which is closely
associated with cervical carcinogenesis (Kwan et al., 2013). Hence, targeting this pathway
might be a promising molecular therapeutic approach for CC.
A recent study proposed that in gastric cancer, TFF1 depletion induces cellular proliferation
via β-catenin signaling. TFF1 induced the activation of protein phosphatase 2A (PP2A) and
glycogen synthase kinase 3 (GSK3β) which in turn were reported to regulate the AKT-βcatenin signaling negatively. This was reflected in the expression levels of downstream
targets c-MYC and Cyclin D1 (Soutto et al., 2015). In line with these results, we observed
decreased expression of β-catenin in COBRA1 siRNA treated cells compared to negative
siRNA treated cells. This decrease was found to be statistically significant at a p-value
<0.05. Thus, the upregulation of TFF1 upon COBRA1 silencing was associated with
decreased β-catenin expression.

4.6 Effect on mRNA expression of survivin
Survivin is a member of the inhibitor of apoptosis proteins (IAP) family with its expression
known to be associated with cellular proliferation, angiogenesis and inhibition of apoptosis
(Fan & Chen, 2017). Identifying the role of survivin in cancer emerged from the findings
that it is highly expressed in most human cancers as well as during development while it is
undetectable in non-proliferating differentiated adult tissues (Li, 2005). Survivin gene is
located on chromosome 17q25 and it encodes multiple splice variants which include wildtype survivin, survivin 2B, survivin DeltaEx3, survivin 3B, survivin 2α and survivin 3α
(Garg et al., 2016; Jaiswal et al., 2015). In cancer cells, it was reported that all these
isoforms are expressed at very high levels compared to normal tissues and was found to be
correlated to tumor aggressiveness and treatment resistance (Jaiswal et al., 2015). The role
of survivin, survivin 2B and survivin DeltaEx3 in cancer has been extensively studied with
results indicating an anti-apoptotic effect for both wild-type survivin and survivin DeltaEx3
while survivin 2B was shown to have pro-apoptotic action. The fact that there are many
splice variants of survivin with even different subcellular pools adds to the complexity of
survivin’s biological functions (Garg et al., 2016; Li, 2005). It is worth mentioning that the
expression of survivin has been reported to be regulated by the Wnt signalling pathway
(Garg et al., 2016; Jaiswal et al., 2015). It has been proposed that the alternative splicing
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of survivin might serve as a mechanism by which cancer cells maintain their proliferation,
yet this requires further investigations (Garg et al., 2016). Notably, NELF complex; having
the RNA recognition motif present in NELF-E subunit, was found to possess a dual function
of transcription regulation and RNA processing. With COBRA1’S role in attenuating steroid
hormones regulated transcription via recruitment of NELF complex to the promotor of target
genes, it was also found to mediate alternative splicing by promoting inclusion of exons and
attenuating skipping (Sun et al., 2007).
In 2017, a systematic meta-analysis was done by Fan and Chen to evaluate the clinical
significance of survivin expression in CC using data from 18 studies with 791 CC patients,
1013 CIN lesions, 199 normal cervical tissues and 95 chronic cervicitis samples. Results
indicated the presence of higher expression levels of survivin in CC relative to other tested
groups. In addition, expression was elevated in high-grade than in low-grade patients, in
advanced stage than in early stage patients and in patients with lymph node metastasis
relative to those without. Also, higher expression was noted in SCC than in AC, yet this
specific result has to be carefully considered as only 55 AC patients were included in this
study compared to 302 SCC patients (Fan & Chen, 2017).
In the present study, we observed decreased expression of β-catenin in COBRA1 siRNA
treated cells compared to negative siRNA treated cells. This decrease was found to be
statistically significant at a p-value <0.05. The results obtained at the β-catenin mRNA
levels were in accordance with results obtained when investigating the expression levels of
survivin, where a decreased expression of the three isoforms; wild-type survivin, survivin
2B and survivin DeltaEx3 was observed. Yet, this decrease was found to be statistically
significant except for wild-type survivin. This might account for the insignificant effect of
COBRA1 on the proliferation and migration of HeLa since the wild-type survivin, which is
the predominantly expressed variant in HeLa, was the least to be affected by COBRA1
depletion. Still, it will be interesting to further test the transduction of this decrease along
the apoptosis signaling pathway by examining the protein levels of caspases 3 and 9 which
are known to be inhibited by survivin.
Taken together, COBRA1 depletion resulted in an increase in the expression of TFF1
accompanied by a subsequent decrease in the β-catenin and survivin expressions at the
mRNA level suggesting that COBRA1 might have an effect on the Wnt/β-catenin signaling
pathway (Figure 13). It will be interesting to investigate the protein levels of the examined
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genes using Western Blot. This could validate if the observed alterations at the mRNA levels
were transmitted to the protein levels of the tested genes.
Since the effect of COBRA1 on TFF1 in gastric cancer was suggested to be through the
inhibition of the AP-1 complex transactivation of TFF1, performing Co-IP and ChIP assays
will be of value in examining the binding of COBRA1 to AP-1 and their possible interaction
with the TFF1 promotor.
The observed effect of COBRA1 on the TFF1/β-catenin signaling axis may represent one of
the molecular mechanisms underlying the potential role of COBRA1 in cervical cancer. Yet,
the finding that the noted decrease in β-catenin and survivin was not reflected on the
proliferation and migration abilities of HeLa is not conclusive and requires further
investigations.
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COBRA1 silencing

Figure 13. Schematic diagram illustrating the consequences of COBRA1 silencing on
mRNA expression levels of examined genes. Successful COBRA1 depletion in HeLa cells
caused a significant increase in the expression of TFF1 leading to decreased expression
levels of the β-catenin and its decreased entry to the nucleus. This resulted in decreased
levels of β-catenin downstream target gene, survivin.
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5. CONCLUSION
As to our knowledge, this is the first study addressing the potential role of COBRA1 in CC.
In summary, our data mining results showed that a statistically significant overexpression
of COBRA1 in cervical carcinoma tissues versus normal cervical tissues was observed and
found to be consistent in two microarray datasets out of the four identified by searching the
publicly available Oncomine cancer microarray dataset. Results from the other two datasets
were found to be contradictory and statistically insignificant.
Results obtained from semi-quantitative RT-PCR analysis of the NELF complex subunits
showed no significant difference in their mRNA levels upon COBRA1 knockdown which
is consistent with previous results suggesting the presence of tight post-transcriptional
regulation of the NELF complex.
The insignificant effect of COBRA1 silencing on the proliferation and migration abilities of
HeLa cells under the applied experimental conditions cannot be conclusive and requires
further investigations.
The observed decrease in the β-catenin expression in COBRA1 siRNA treated cells
compared to the negative siRNA treated cells was found to be statistically significant and
was accompanied by comparable decrease in survivin expression suggesting an effect for
COBRA1 depletion on the Wnt/β-catenin signaling pathway. COBRA1 silencing resulted
in a significant increase of TFF1 which could be the modulator of the effects observed on
the β-catenin expression.
Altogether, this study could help as an initial step in identifying the role of COBRA1 in
cervical cancer tumorigenesis.
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6. FUTURE DIRECTIONS
More research is needed to further characterize the role of COBRA1 in cervical cancer and
help clarify the possibility of it being a suitable prognostic and therapeutic target in CC.
Since this study was limited by the use of one type of CC cell lines; HeLa, therefore
extending the methodology to include more CC cell lines representing the squamous cell
cervical carcinoma which is the most common subtype will help provide a more reliable
evaluation of COBRA1’s role in CC.
Further analyses of COBRA1 knocked cells relative to control cells using mRNA
microarrays will help provide a larger view of the involved genetic pathways and their
possible role in CC progression. In addition, studying the effect of COBRA1 knockdown on
cell cycle distribution using flow cytometry could also help clarify the role of COBRA1
mediated regulation of gene expression in HeLa cells. It will be also interesting to investigate
the effect of complete Knockout of COBRA1in HeLa using Crisper/Cas systems.
It is also worth mentioning that under the applied experimental conditions, none of the tested
conditions was supplied with exogenous estrogen during the transfection process. Hence,
the consequences of adding exogenous estrogen together with the silencing process could
be worth testing.

47

REFERENCES
Aiyar, S., Blair, A., Hopkinson, D., Bekiranov, S., & Li, R. (2007). Regulation of clustered
gene expression by cofactor of BRCA1 (COBRA1) in breast cancer cells. Oncogene,
26(18), 2543–2553. https://doi.org/10.1038/sj.onc.1210047
Aiyar, S., Cho, H., Lee, J., & Li, R. (2007). Concerted transcriptional regulation by
BRCA1 and COBRA1 in breast cancer cells. International Journal of Biological
Sciences, 3(7), 486–492. https://doi.org/10.7150/ijbs.3.486
Aiyar, S., Sun, J., Blair, A., Moskaluk, C., Lu, Y., Ye, Q., … Li, R. (2004). Attenuation of
estrogen receptor α-mediated transcription through estrogen-stimulated recruitment of
a negative elongation factor. Genes and Development, 18(17), 2134–2146.
https://doi.org/10.1101/gad.1214104
Amleh, A., Nair, S. J., Sun, J., Sutherland, A., Hasty, P., & Li, R. (2009). Mouse cofactor
of BRCA1 (Cobra1) is required for early embryogenesis. PLoS ONE, 4(4), 2–9.
https://doi.org/10.1371/journal.pone.0005034
Arbyn, M., Castellsagué, X., de sanjosé, S., Bruni, L., Saraiya, M., Bray, F., & Ferlay, J.
(2011). Worldwide burden of cervical cancer in 2008. Annals of Oncology, 22(12),
2675–2686. https://doi.org/10.1093/annonc/mdr015
Biewenga, P., Buist, M. R., Moerland, P. D., van Themaat, E. V. L., van Kampen, A. H.
C., ten Kate, F. J. W., & Baas, F. (2008). Gene expression in early stage cervical
cancer. Gynecologic Oncology, 108, 520–526.
https://doi.org/10.1016/j.ygyno.2007.11.024
Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch
FX, de S. S. 27. (2017). Human Papillomavirus and Related Diseases in the World.
Summary Report. ICO/IARC Information Centre on HPV and Cancer (HPV
Information Centre).
Cao, H.-Z., Liu, X.-F., Yang, W.-T., Chen, Q., & Zheng, P.-S. (2017). LGR5 promotes
cancer stem cell traits and chemoresistance in cervical cancer. Cell Death and
Disease, 8(9), e3039. https://doi.org/10.1038/cddis.2017.393
Chai, H., & Yang, Y. (2014). Effects of MACC1 siRNA on biological behaviors of HeLa,
1271–1280. https://doi.org/10.1007/s00404-013-3126-z
48

Chung, S., Franceschi, S., & Lambert, P. F. (2010). Estrogen and ERα: Culprits in Cervical
Cancer? Trends in Endocrinology and Metabolism, 21(8), 504–511.
https://doi.org/doi:10.1016/j.tem.2010.03.005
Chung, S. H., Franceschi, S., & Lambert, P. F. (2010). Estrogen and ERα: Culprits in
cervical cancer? Trends in Endocrinology and Metabolism.
https://doi.org/10.1016/j.tem.2010.03.005
Colombo, N., Carinelli, S., Colombo, A., Marini, C., Rollo, D., & Sessa, C. (2012).
Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and
follow-up. Annals of Oncology, 23(SUPPL. 7).
https://doi.org/10.1093/annonc/mds268
Dasari, S., Wudayagiri, R., & Valluru, L. (2015). Cervical cancer: Biomarkers for
diagnosis and treatment. Clinica Chimica Acta, 445, 7–11.
https://doi.org/10.1016/j.cca.2015.03.005
De Freitas, A. C., Coimbra, E. C., & Leitão, M. da C. G. (2014). Molecular targets of HPV
oncoproteins: Potential biomarkers for cervical carcinogenesis. Biochimica et
Biophysica Acta - Reviews on Cancer, 1845(2), 91–103.
https://doi.org/10.1016/j.bbcan.2013.12.004
El Zeneini, E., Kamel, S., El-Meteini, M., & Amleh, A. (2017). Knockdown of COBRA1
decreases the proliferation and migration of hepatocellular carcinoma cells. Oncology
Reports, 37(3), 1896–1906. https://doi.org/10.3892/or.2017.5390
Fan, Y., & Chen, J. (2017). Clinicopathological significance of survivin expression in
patients with cervical cancer: A systematic meta-analysis. Bioengineered, 8(5), 511–
523. https://doi.org/https://dx.doi.org/10.1080/21655979.2016.1252879
Garg, H., Suri, P., Gupta, J. C., Talwar, G. P., & Dubey, S. (2016). Survivin: A unique
target for tumor therapy. Cancer Cell International, 16(1), 1–14.
https://doi.org/10.1186/s12935-016-0326-1
Gien, L. T., Beauchemin, M. C., & Thomas, G. (2010). Adenocarcinoma: A unique
cervical cancer. Gynecologic Oncology, 116(1), 140–146.
https://doi.org/10.1016/j.ygyno.2009.09.040
Gilchrist, D. A., Dos Santos, G., Fargo, D. C., Xie, B., Gao, Y., Li, L., & Adelman, K.
49

(2010). Pausing of RNA polymerase II disrupts DNA-specified nucleosome
organization to enable precise gene regulation. Cell, 143(4), 540–551.
https://doi.org/10.1016/j.cell.2010.10.004
Gilchrist, D. A., Nechaev, S., Lee, C., Ghosh, S. K. B., Collins, J. B., Li, L., … Adelman,
K. (2008). NELF-mediated stalling of Pol II can enhance gene expression by blocking
promoter-proximal nucleosome assembly. Genes and Development, 22(14), 1921–
1933. https://doi.org/10.1101/gad.1643208
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell,
144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013
Hess, J., Angel, P., & Schorpp-Kistner, M. (2004). AP-1 subunits: quarrel and harmony
among siblings. Journal of Cell Science, 117(25), 5965–5973.
https://doi.org/10.1242/jcs.01589
Hildesheim, A., & Berrington de González, A. (2006). Etiology and prevention of cervical
adenocarcinomas. Journal of the National Cancer Institute, 98(5), 292–293.
https://doi.org/10.1093/jnci/djj098
Hong, S. W., Jiang, Y., Kim, S., Li, C. J., & Lee, D. (2014). Target Gene Abundance
Contributes to the Efficiency of siRNA-Mediated Gene Silencing. Nucleic Acid
Therapeutics, 24(3), 192–198. https://doi.org/10.1089/nat.2013.0466
Jaiswal, P. K., Goel, A., & Mittal, R. D. (2015). Survivin: A molecular biomarker in
cancer. Indian Journal of Medical Research, 142(April), 389–397.
https://doi.org/10.4103/0971-5916.159250
Kamel, S. (2012). Correlating the expression levels of COBRA1 (co-factor of BRCA1)
with hepatocellular carcinoma development in Egyptian patients. American
University in Cairo.
Kininis, M., Isaacs, G., Core, L., Hah, N., & Kraus, W. (2009). Postrecruitment Regulation
of RNA Polymerase II Directs Rapid Signaling Responses at the Promoters of
Estrogen Target Genes. Molecular and Cellular Biology, 29(5), 1123–1133.
https://doi.org/10.1128/MCB.00841-08
Kwan, H. T., Chan, D. W., Cai, P. C. H., Mak, C. S. L., Yung, M. M. H., Leung, T. H. Y.,
… Ngan, H. Y. S. (2013). AMPK Activators Suppress Cervical Cancer Cell Growth
50

through Inhibition of DVL3 Mediated Wnt/β-Catenin Signaling Activity. PLoS ONE,
8(1), 1–10. https://doi.org/10.1371/journal.pone.0053597
Leung, W. K., Yu, J., Chan, F. K. L., To, K. F., Chan, M. W. Y., Ebert, M. P. A., … Sung,
J. J. Y. (2002). Expression of trefoil peptides (TFFI, TFF2, and TFF3) in gastric
carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues. Journal of
Pathology, 197(5), 582–588. https://doi.org/10.1002/path.1147
Li, F. (2005). Role of survivin and its splice variants in tumorigenesis. British Journal of
Cancer, 92, 212–216. https://doi.org/10.1038/sj.bjc.6602340
Liu, Y., Tian, L.-B., Yang, H.-Y., & Zhang, H.-P. (2017). Effects of estradiol and
progesterone on growth of cervical cancer cell line in vitro. European Review for
Medical and Pharmacological Sciences, 21, 3959–3965.
Lucey, B. P., Nelson-Rees, W. A., & Hutchins, G. M. (2009). Historical Perspective
Henrietta Lacks, HeLa Cells, and Cell Culture Contamination. Arch Pathol Lab Med,
133(9), 1463–1467. https://doi.org/10.1043/1543-2165-133.9.1463
Masiakowski, P., Breathnach, R., Bloch, J., Gannon, F., Krust, A., & Chambon, P. (1982).
Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human
breast cancer cell line. Nucleic Acids Research, 10(24), 7895–7903.
https://doi.org/10.1093/nar/10.24.7895
McChesney, P. A., Aiyar, S. E., Lee, O. J., Zaika, A., Moskaluk, C., Li, R., & El-Rifai, W.
(2006). Cofactor of BRCA1: A novel transcription factor regulator in upper
gastrointestinal adenocarcinomas. Cancer Research, 66(3), 1346–1353.
https://doi.org/10.1158/0008-5472.CAN-05-3593
Nair, H. B., Luthra, R., Kirma, N., Liu, Y. G., Flowers, L., Evans, D., & Tekmal, R. R.
(2005). Induction of aromatase expression in cervical carcinomas: Effects of
endogenous estrogen on cervical cancer cell proliferation. Cancer Research, 65(23),
11164–11173. https://doi.org/10.1158/0008-5472.CAN-05-1087
Narita, T., Yamaguchi, Y., Yano, K., Chanarat, S., Wada, T., Kim, D., … Handa, H.
(2003). Human Transcription Elongation Factor NELF : Identification of Novel
Subunits and Reconstitution of the Functionally Active Complex. Molecular and
Cellular Biology, 23(6), 1863–1873. https://doi.org/10.1128/MCB.23.6.1863

51

Newton, C. L., & Mould, T. A. (2017). Invasive cervical cancer. Obstetrics, Gynaecology
and Reproductive Medicine, 27(1), 7–13. https://doi.org/10.1016/j.ogrm.2016.11.002
Pérez-Plasencia, C., Dueñas-Gonzalez, A., & Bustos-Martínez, J. (2008). Second hit in
cervical carcinogenesis process: involvement of wnt/beta catenin pathway.
International Archives of Medicine, 4(5). https://doi.org/10.1186/1755-7682-1-10
Pohl, G. (2005). Inactivation of the Mitogen-Activated Protein Kinase Pathway as a
Potential Target-Based Therapy in Ovarian Serous Tumors with KRAS or BRAF
Mutations. Cancer Research, 65(5), 1994–2000. https://doi.org/10.1158/00085472.CAN-04-3625
Pyeon, D., Newton, M. A., Lambert, P. F., Den Boon, J. A., Sengupta, S., Marsit, C. J., …
Ahlquist, P. (2007). Fundamental differences in cell cycle deregulation in human
papillomavirus-positive and human papillomavirus-negative head/neck and cervical
cancers. Cancer Research, 67(10), 4605–4619. https://doi.org/10.1158/00085472.CAN-06-3619
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., …
Chinnaiyan, A. M. (2004). ONCOMINE: A Cancer Microarray Database and
Integrated Data-Mining Platform. Neoplasia, 6(1), 1–6.
https://doi.org/10.1016/S1476-5586(04)80047-2
Rosen, E. M., Fan, S., Pestell, R. G., & Goldberg, I. D. (2003). BRCA1 gene in breast
cancer. Journal of Cellular Physiology, 196(1), 19–41.
https://doi.org/10.1002/jcp.10257
Scholzen, T., & Gerdes, J. (2000). The Ki-67 protein: from the known and the unknown.
Journal of Cellular Physiology, 182(August 1999), 311–322.
https://doi.org/10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
Scotto, L., Narayan, G., Nandula, S., Arias-Pulido, H., Subramaniyam, Schneider, A., …
V. Murty, V. (2008). Identification of Copy Number Gain and Overexpressed Genes
on Chromosome Arm 20q by an Integrative Genomic Approach in Cervical Cancer:
Potential Role in Progression. Genes, Chromosomes & Cancer, 47, 755–765.
https://doi.org/10.1002/gcc
Shaulian, E., & Karin, M. (2001). AP-1 in cell proliferation and survival. Oncogene, 20,
2390–2400.
52

Sims, R. J., Belotserkovskaya, R., & Reinberg, D. (2004). Elongation by RNA polymerase
II : the short and long of it. Genes & Development, 18(20), 2437–2468.
https://doi.org/10.1101/gad.1235904
Soutto, M., Peng, D. F., Katsha, A., Chen, Z., Piazuelo, M. B., Washington, M. K., … ElRifai, W. (2015). Activation of β-catenin signalling by TFF1 loss promotes cell
proliferation and gastric tumorigenesis. Gut, 64(7), 1028–1039.
https://doi.org/10.1136/gutjnl-2014-307191
Sudhir, P. R., Hsu, C. L., Wang, M. J., Wang, Y. T., Chen, Y. J., Sung, T. Y., … Chen, J.
Y. (2011). Phosphoproteomics identifies oncogenic ras signaling targets and their
involvement in lung adenocarcinomas. PLoS ONE, 6(5).
https://doi.org/10.1371/journal.pone.0020199
Sun, J., Blair, A. L., Aiyar, S. E., & Li, R. (2007). Cofactor of BRCA1 modulates
androgen-dependent transcription and alternative splicing. Journal of Steroid
Biochemistry and Molecular Biology, 107(3–5), 131–139.
https://doi.org/10.1016/j.jsbmb.2007.05.031
Sun, J., & Li, R. (2010). Human negative elongation factor activates transcription and
regulates alternative transcription initiation. Journal of Biological Chemistry, 285(9),
6443–6452. https://doi.org/10.1074/jbc.M109.084285
Sun, J., Pan, H., Lei, C., Yuan, B., Nair, S. J., April, C., … Li, R. (2011). Genetic and
genomic analyses of RNA polymerase II-pausing factor in regulation of mammalian
transcription and cell growth. Journal of Biological Chemistry, 286(42), 36248–
36257. https://doi.org/10.1074/jbc.M111.269167
Sun, J., Watkins, G., Blair, A. L., Moskaluk, C., Ghosh, S., Jiang, W. G., & Li, R. (2008).
Deregulation of cofactor of BRCA1 expression in breast cancer cells. Journal of
Cellular Biochemistry, 103(6), 1798–1807. https://doi.org/10.1002/jcb.21568
Tanaka, T., Nakamura, J., Kitajima, Y., Kai, K., Miyake, S., Hiraki, M., … Noshiro, H.
(2013). Loss of trefoil factor 1 is regulated by DNA methylation and is an
independent predictive factor for poor survival in advanced gastric cancer.
International Journal of Oncology, 42(3), 894–902.
https://doi.org/10.3892/ijo.2013.1759

53

Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-tieulent, J., & Jemal, A. (2015).
Global Cancer Statistics, 2012. CA: A Cancer Journal of Clinicians., 65(2), 87–108.
https://doi.org/10.3322/caac.21262.
Uyar, D., & Rader, J. (2014). Genomics of cervical cancer and the role of human
papillomavirus pathobiology. Clinical Chemistry, 60(1), 144–146.
https://doi.org/10.1373/clinchem.2013.212985
Yamaguchi, Y., Takagi, T., Wada, T., Yano, K., Furuya, A., Sugimoto, S., … Handa, H.
(1999). NELF, a multisubunit complex containing RD, cooperates with DSIF to
repress RNA polymerase II elongation. Cell, 97(1), 41–51.
https://doi.org/10.1016/S0092-8674(00)80713-8
Yang, Z., Chen, S., Luan, X., Li, Y., Liu, M., & Li, X. (2009). MicroRNA-214 is
Aberrantly Expressed in Cervical Cancers and Inhibits the Growth of HeLa Cells,
61(November), 1075–1082. https://doi.org/10.1002/iub.252
Ye, Q., Hu, Y. F., Zhong, H., Nye, A. C., Belmont, A. S., & Li, R. (2001). BRCA1induced large-scale chromatin unfolding and allele-specific effects of cancerpredisposing mutations. Journal of Cell Biology, 155(6), 911–921.
https://doi.org/10.1083/jcb.200108049
Youssef, A., Shawer, H., Afify, A., & Amleh, A. (2016). The potential involvement of the
cofactor of BRCA1 in hepatocellular carcinoma pathogenesis. Advances in Modern
Oncology Research, 2(4), 1–12. https://doi.org/10.18282/amor.v2.i4.129
Zhai, Y., Kuick, R., Nan, B., Ota, I., Weiss, S. J., Trimble, C. L., … Cho, K. R. (2007).
Gene expression analysis of preinvasive and invasive cervical squamous cell
carcinomas identifies HOXC10 as a key mediator of invasion. Cancer Research,
67(21), 10163–10172. https://doi.org/10.1158/0008-5472.CAN-07-2056
Zhong, H., Zhu, J., Zhang, H., Ding, L., Sun, Y., Huang, C., & Ye, Q. (2004). COBRA1
inhibits AP-1 transcriptional activity in transfected cells. Biochemical and
Biophysical Research Communications, 325(2), 568–573.
https://doi.org/10.1016/j.bbrc.2004.10.079
Zhu, J., Song, S., Jiang, Z., Yan, J., Lu, Q., Huang, C., & Ye, Q. (2004). Characterization
of COBRA1 in human breast cancer cell lines using a new polyclonal antibody
against COBRA1. IUBMB Life, 56(3), 161–6.
54

https://doi.org/10.1080/15216540410001699826
Zhu, K., Chen, L., Han, X., Wang, J. I. A., & Wang, J. U. E. (2012). Short hairpin RNA
targeting Twist1 suppresses cell proliferation and improves chemosensitivity to
cisplatin in HeLa human cervical cancer cells, 1027–1034.
https://doi.org/10.3892/or.2012.1633

55

